Jump Financial’s Keros Therapeutics KROS Stock Holding History

Jump Financial’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$165K	Sell	15,400 -34,993	-69%	-$390K	﹤0.01%	1875
2026 Q1	$556K	Sell	50,393 -110,743	-69%	-$1.71M	0.01%	1188
2025 Q4	$3.28M	Buy	+161,136	New	+$2.83M	0.04%	501
2025 Q2	–	Sell	-103,826	Closed	-$1.06M	–	1991
2025 Q1	$1.06M	Buy	+103,826	New	+$1.21M	0.01%	806
2024 Q4	–	Sell	-15,503	Closed	-$900K	–	1839
2024 Q3	$900K	Buy	15,503 +1,822	+13%	+$90K	0.02%	841
2024 Q2	$625K	Buy	+13,681	New	+$735K	0.01%	1039
2023 Q3	–	Sell	-7,283	Closed	-$293K	–	2066
2023 Q2	$293K	Buy	+7,283	New	+$319K	0.01%	1319
2022 Q4	–	Sell	-8,344	Closed	-$314K	–	1828
2022 Q3	$314K	Sell	8,344 -13,634	-62%	-$473K	0.01%	1123
2022 Q2	$607K	Buy	+21,978	New	+$964K	0.03%	763

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jump Financial's KROS Position: Q2 2026 in Review

Jump Financial reduced its Keros Therapeutics (KROS) stake by 69% in Q2 2026, selling an estimated $390K and leaving 15,400 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #1875.

Jump Financial first reported a position in KROS in Q2 2022 and has held it in 9 quarters since. The position peaked at $3.28M in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Jump Financial held 15,400 shares of Keros Therapeutics worth $165K as of Q2 2026.
Jump Financial sold 34,993 Keros Therapeutics shares in Q2 2026, an estimated $390K.
Keros Therapeutics made up ﹤0.01% of Jump Financial's portfolio in Q2 2026, its #1875 holding.
Jump Financial first reported a position in Keros Therapeutics in Q2 2022 and has held it in 9 quarters since.
Jump Financial's Keros Therapeutics position peaked at $3.28M in Q4 2025.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.